Canada's Clinical Trial Market:
A Strategic Alternative

Canada commands 4% of global clinical trials despite having a population just 12% the size of the United States’, highlighting untapped potential as sponsors navigate volatility elsewhere. Geopolitical uncertainty and policy shifts affecting traditional research hubs are driving life sciences companies to consider Canada's stable regulatory environment, robust site infrastructure, and proximity to major markets as key advantages for global trial strategies.

This Industry Outlook Report explores Canada's evolving role in clinical trials, from its balanced early- and late-phase trial distribution to provincial incentives fueling growth across therapeutic areas. It highlights how Canada's regulatory parity, tax advantages, and cultural factors create opportunities for sponsors to diversify their research footprint while maintaining efficiency. Read to learn about: 

• Canada's 30-day regulatory timeline and SR&ED tax credits
• Provincial data sharing rules impacting trials
• Canada's trial phase split vs. U.S. patterns

​